To the Editor: In the 3 November 2008 issue of the Journal, Millar recommends against routine thromboprophylaxis in medical patients.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
All authors are members of the Australia and Zealand Working Party on the Management and Prevention of Venous Thromboembolism. John Fletcher has received speaker fees and travel assistance from Sanofi-Aventis and GlaxoSmithKline, and a speaker fee from Bayer Schering Pharma. Donald MacLellan has received non-directed educational grants from a number of pharmaceutical and non-pharmaceutical companies, including Sanofi-Aventis, to allay costs in the production of the Prevention of venous thromboembolism booklets. Harry Gibbs has received clinical trial funding, consultancy fees, honoraria and travel grants from a number of pharmaceutical and medical device companies, including Sanofi-Aventis, Pfizer and Boehringer Ingelheim. Geoff Matthews received travel assistance from Sanofi-Aventis.